Placental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primates

Stem Cells

Volumn 25, Issue 1, 2007, Pages 252-261

  Carlo Stella, Carmelo ^a,b   Di Nicola, Massimo ^a   Longoni, Paolo ^a   Cleris, Loredana ^a   Lavazza, Cristiana ^a   Milani, Raffaella ^a   Milanesi, Marco ^a   Magni, Michele ^a   Pace, Virgilio ^c   Colotta, Francesco ^c   Avanzini, Maria A ^d   Formelli, Franca ^a   Gianni, Alessandro M ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Chemistry Section   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Granulocyte colony stimulating factor; Placental growth factor; Stem cell mobilization; Stem cell transplantation

Indexed keywords

GELATINASE B; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PLACENTAL GROWTH FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HEMATOPOIETIC SYSTEM; IRRADIATION; LEUKOCYTE COUNT; MALE; MONONUCLEAR CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; RHESUS MONKEY; STEM CELL MOBILIZATION; THROMBOCYTE ACTIVATION;

ANIMALS; COLONY-FORMING UNITS ASSAY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GROWTH SUBSTANCES; HUMANS; LEUKOCYTES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; PLACENTA; PREGNANCY; PREGNANCY PROTEINS; PRIMATES; RECOMBINANT PROTEINS;

MACACA MULATTA; PRIMATES;

EID: 33846004142     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0020     Document Type: Article

References (62)

1. Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol 2001;38:21-27.
2. Ferme C, Mounier N, Divine M et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002;20:467-475.
3. Gianni AM. High-dose chemotherapy and autotransplants: A time for guidelines. Ann Oncol 1997;8:933-935.
4. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-1297.
5. Appelbaum FR. Choosing the source of stem cells for allogeneic transplantation: No longer a peripheral issue. Blood 1999;94:381-383.
6. Aversa F, Tabilio A, Terenzi A et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-3955.
7. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-181.
8. Demirer T, Bensinger WI, Buckner CD. Peripheral blood stem cell mobilization for high-dose chemotherapy. J Hematother 1999;8:103-113.
9. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-3794.
10. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3970-3978.
11. Tarella C, Di Nicola M, Caracciolo D et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: An indication for patients at risk for low mobilization. Bone Marrow Transplant 2002;30:725-732.
12. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-3969.
13. Carlo-Stella C, Di Nicola M, Magni M et al. Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. Cancer Res 2002;62:6152-6157.
14. Craddock CF, Nakamoto B, Andrews RG et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997;90:4779-4788.
15. King AG, Horowitz D, Dillon SB et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. Blood 2001;97:1534-1542.
16. Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-2730.
17. Bishop MR, Jackson JD, O'Kane-Murphy B et al. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. J Clin Oncol 1996;14:2521-2526.
18. Brasel K, McKenna HJ, Charrier K et al. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 1997;90:3781-3788.
19. Koc ON, Gerson SL, Cooper BW et al. Randomized cross-over trial of progenitor-cell mobilization: High-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000;18:1824-1830.
20. Rosenfeld CS, Bolwell B, LeFever A et al. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. Bone Marrow Transplant 1996;17:179-183.
21. Shpall EJ, Wheeler CA, Turner SA et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999;93:2491-2501.
22. Stiff P, Gingrich R, Luger S et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000;26:471-481.
23. To LB, Bashford J, Durrant S et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003;31:371-378.
24. Fruehauf S, Seggewiss R. It's moving day: Factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. Br J Haematol 2003;122:360-375.
25. Kessinger A, Sharp JG. The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003;31:319-329.
26. + hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300.
27. Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-1318.
28. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-1102.
29. + cells in poor mobilizers. Blood 2004;103:3287-3295.
30. Cao Y, Ji WR, Qi P et al. Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Commun 1997;235:493-498.
31. Maglione D, Guerriero V, Viglietto G et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991;88:9267-9271.
32. Maglione D, Guerriero V, Viglietto G et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993;8:925-931.
33. Yang W, Ahn H, Hinrichs M et al. Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol 2003;60:53-60.
34. Carmeliet P, Moons L, Luttun A et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-583.
35. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
36. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9:702-712.
37. Hattori K, Heissig B, Wu Y et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002;8:841-849.
38. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 1988;58:109-113.
39. Molineux G, McCrea C, Yan XQ et al. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 1997;89:3998-4004.
40. Sudo Y, Shimazaki C, Ashihara E et al. Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 1997;89:3186-3191.
41. Carlo-Stella C, Di Nicola M, Milani R et al. Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. Exp Hematol 2004;32:171-178.
42. Humphries RK, Eaves AC, Eaves CJ. Characterization of a primitive erythropoietic progenitor found in mouse marrow before and after several weeks in culture. Blood 1979;53:746-763.
43. Moore KA, Ema H, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 1997;89:4337-4347.
44. Sutherland HJ, Eaves CJ, Eaves AC et al. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 1989;74:1563-1570.
45. Pruijt JF, van Kooyk Y, Figdor CG et al. Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. Blood 1998;91:4099-4105.
46. Carlo-Stella C, Di Nicola M, Longoni P et al. Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. Exp Hematol 2004;32:68-75.
47. + cells that rapidly engraft lethally x-irradiated nonhuman primates. Exp Hematol 1999;27:1557-1568.
48. Freireich EJ, Gehan EA, Rall DP et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-244.
49. Lemieux ME, Rebel VI, Lansdorp PM et al. Characterization and purification of a primitive hematopoietic cell type in adult mouse marrow capable of lymphomyeloid differentiation in long-term marrow "switch" cultures. Blood 1995;86:1339-1347.
50. Sutherland HJ, Eaves CJ, Lansdorp PM et al. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991;78:666 -672.
51. Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-637.
52. McQuibban GA, Butler GS, Gong JH et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001;276:43503-43508.
53. Pelus LM, Bian H, King AG et al. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood 2004;103:110-119.
54. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-694.
55. Eriksson U, Alitalo K. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Nat Med 2002;8:775-777.
56. Fejer G, Szalay K, Gyory I et al. Adenovirus infection dramatically augments lipopolysaccharide-induced TNF production and sensitizes to lethal shock. J Immunol 2005;175:1498-1506.
57. Levesque JP, Hendy J, Takamatsu Y et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003;111:187-196.
58. Levesque JP, Hendy J, Winkler IG et al. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol 2003;31:109-117.
59. Levesque JP, Takamatsu Y, Nilsson SK et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001;98:1289-1297.
60. Shi PA, Pomper GJ, Metzger ME et al. Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models. Transfusion 2001;41:1438-1444.
61. Gerber HP, Malik AK, Solar GP et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954-958.
62. Luttun A, Tjwa M, Moons L et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-840.